AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20206052 — intervention group
Group type: COMPARATOR
Intervention: Patient satisfaction
Number of subjects: 13
Study 20206052 — intervention group
Group type: EXPERIMENTAL
Intervention: FNB
Number of subjects: 13
Study 17095263 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine buccal infiltration during each of the 5 phases of the menstrual cycle for groups 1 and 2; randomly selected day for group 3.
Number of subjects: 30
Study 15866643 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg/week) with vitamin D and calcium
Number of subjects: 25
Study 15866643 — intervention group
Group type: COMPARATOR
Intervention: Control group (vitamin D and calcium only)
Number of subjects: 25
Study 12060505 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole, 150 mg capsules, single dose repeated weekly for 2 weeks
Number of subjects: 128
Study 12060505 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole, 200 mg tablets, single dose repeated weekly for 2 weeks
Number of subjects: 128
Study 11158921 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training for 3 months
Number of subjects: 39
Study 11158921 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention (control)
Number of subjects: 39
Study 9553546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented stems
Number of subjects: 200
Study 9553546 — intervention group
Group type: COMPARATOR
Intervention: Noncemented stems
Number of subjects: 200
Study 9553546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented stems (matched pairs)
Number of subjects: 200
Study 9553546 — intervention group
Group type: COMPARATOR
Intervention: Noncemented stems (matched pairs)
Number of subjects: 200
Study 8184812 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin (40 mg/day)
Number of subjects: 24
Study 8184812 — intervention group
Group type: EXPERIMENTAL
Intervention: pravastatin (40 mg/day)
Number of subjects: 24
Study 8184812 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 8184812 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin and pravastatin
Number of subjects: 24
Study 2453699 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antiarrhythmic agents (quinidine, etmozin, disopyramide, mexitil, and allapinine)
Number of subjects: 24
Study 29750926 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated postpartum IUD inserter
Number of subjects: 500
Study 29750926 — intervention group
Group type: COMPARATOR
Intervention: Modified Kelly placental forceps
Number of subjects: 500
Study 26582645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment serum d-2-hydroxyglutarate (D2HG) levels
Number of subjects: 84
Study 25705952 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional 10,600‐nm CO2 laser treatment (3 treatments at 8-week intervals)
Number of subjects: 25
Study 23901675 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy for 4 weeks
Number of subjects: 24
Study 23901675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 20630042 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose (600 mg IV)
Number of subjects: 200
Study 20630042 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 200
Study 18234127 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief high-impact unilateral exercises
Number of subjects: 0
Study 18234127 — intervention group
Group type: COMPARATOR
Intervention: Control leg (no intervention)
Number of subjects: 0
Study 16603135 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose acute tryptophan depletion
Number of subjects: 19
Study 16603135 — intervention group
Group type: COMPARATOR
Intervention: Low-dose acute tryptophan depletion
Number of subjects: 19
Study 12595913 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300 to 600 mg, divided in 2 to 3 doses)
Number of subjects: 0
Study 12595913 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (600 to 900 mg/d)
Number of subjects: 0
Study 12595913 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0
Study 10963246 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1 voluntary counselling and testing (VCT)
Number of subjects: 3706
Study 10963246 — intervention group
Group type: COMPARATOR
Intervention: Basic health information
Number of subjects: 3706
Study 8991564 — intervention group
Group type: EXPERIMENTAL
Intervention: ECM proteins (collagen I, collagen IV, fibronectin)
Number of subjects: 14
Study 8991564 — intervention group
Group type: COMPARATOR
Intervention: OKT3 alone
Number of subjects: 14
Study 1467155 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (magnesium pyrrolidone carboxylic acid) at a dose of 360 mg/day
Number of subjects: 0
Study 1467155 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine plus placebo
Number of subjects: 0
Study 29338141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FIB)
Number of subjects: 100
Study 29338141 — intervention group
Group type: COMPARATOR
Intervention: Femoral nerve block
Number of subjects: 100
Study 27050699 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin (0.25%) after 30% SA peel
Number of subjects: 20
Study 27050699 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol (0.25%) after 30% SA peel
Number of subjects: 20
Study 27050699 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin (0.25%)
Number of subjects: 20
Study 27050699 — intervention group
Group type: COMPARATOR
Intervention: Retinol (0.25%)
Number of subjects: 20
Study 24166742 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg daily along with betahistine 16 mg and paracetamol 1 gm during episodes
Number of subjects: 48
Study 24166742 — intervention group
Group type: COMPARATOR
Intervention: Betahistine and paracetamol during episodes
Number of subjects: 48
Study 22906860 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-based composites (bisphenol-A-diglycidyl-dimethacrylate-composite for permanent teeth; urethane dimethacrylate-based polyacid-modified compomer for primary teeth)
Number of subjects: 534
Study 22906860 — intervention group
Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 534
Study 19777177 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with serial [(18)F] FDG-PET
Number of subjects: 66
Study 19059048 — intervention group
Group type: EXPERIMENTAL
Intervention: Carraguard
Number of subjects: 6202
Study 19059048 — intervention group
Group type: COMPARATOR
Intervention: Placebo (methylcellulose)
Number of subjects: 6202
Study 16829617 — intervention group
Group type: EXPERIMENTAL
Intervention: MenBvac vaccine
Number of subjects: 374
Study 14530753 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon sedation regimen
Number of subjects: 21
Study 14530753 — intervention group
Group type: COMPARATOR
Intervention: Standard sedation regimen (intravenous propofol at 0-5 mg.kg-1.hr-1 and alfentanil 30 microg.kg-1.hr-1)
Number of subjects: 21
Study 10968495 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 104
Study 10968495 — intervention group
Group type: COMPARATOR
Intervention: Bronchodilators without inhaled corticosteroids
Number of subjects: 104
Study 10968495 — intervention group
Group type: EXPERIMENTAL
Intervention: PEF data corrected for nonlinearity of PEF meters
Number of subjects: 104
Study 9046643 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertion training therapy
Number of subjects: 0
Study 9046643 — intervention group
Group type: COMPARATOR
Intervention: No assertion training therapy (control)
Number of subjects: 0
Study 9046643 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretesting
Number of subjects: 0
Study 8325071 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (50 Gy)
Number of subjects: 258
Study 8325071 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cisplatin 50 mg/m2 and vindesine 3 mg/m2 for 2 courses)
Number of subjects: 258
Study 3792347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 98
Study 3792347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 3792347 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 98
Study 29929385 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (1000 mg long-acting undecanoate testosterone via intramuscular injection every 3 months)
Number of subjects: 29
Study 29929385 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline serum)
Number of subjects: 29
Study 26139486 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed hands-on training session (Sim group)
Number of subjects: 59
Study 26139486 — intervention group
Group type: COMPARATOR
Intervention: Control group (unstructured hands-on session)
Number of subjects: 59
Study 24051107 — intervention group
Group type: EXPERIMENTAL
Intervention: MedGem handheld device
Number of subjects: 88
Study 24051107 — intervention group
Group type: COMPARATOR
Intervention: Traditional indirect calorimeter
Number of subjects: 88
Study 22230648 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 6mg
Number of subjects: 0
Study 22230648 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 3mg
Number of subjects: 0
Study 22230648 — intervention group
Group type: COMPARATOR
Intervention: Methamphetamine 15mg
Number of subjects: 0
Study 22230648 — intervention group
Group type: COMPARATOR
Intervention: Methamphetamine 30mg
Number of subjects: 0
Study 20188443 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized multifactorial intervention including in-home visits by trained nurse or physician, analytical studies, and a specifically-designed algorithm for risk detection.
Number of subjects: 328
Study 20188443 — intervention group
Group type: COMPARATOR
Intervention: Routine primary care recommendations (Control group).
Number of subjects: 328
Study 19002314 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi
Number of subjects: 53
Study 19002314 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 53
Study 15928719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-arginine (3.0 t.i.d p.o. for 30 days)
Number of subjects: 792
Study 15928719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792
Study 15928719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral L-arginine
Number of subjects: 792
Study 12885747 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9193
Study 12885747 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9193
Study 10338173 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL 1.5% mepivacaine with proximal digital pressure
Number of subjects: 20
Study 10338173 — intervention group
Group type: COMPARATOR
Intervention: 40 mL 1.5% mepivacaine without digital pressure
Number of subjects: 20
Study 8677929 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol inhalation
Number of subjects: 18
Study 8677929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1752075 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly subcutaneous administration of recombinant human erythropoietin (rHuEPO) at a starting dose of 100 U/kg body wt/week
Number of subjects: 20
Study 1752075 — intervention group
Group type: COMPARATOR
Intervention: Twice weekly subcutaneous administration of recombinant human erythropoietin (rHuEPO) at a starting dose of 100 U/kg body wt/week
Number of subjects: 20
Study 6896963 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic tourniquet
Number of subjects: 48
Study 6896963 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tourniquet)
Number of subjects: 48
Study 31203097 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 92
Study 28911144 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (G1) - empiric two-pill/week dose increase followed by subsequent pill-per-week dose adjustments
Number of subjects: 33
Study 28911144 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (G2) - ongoing adjustment based on current TSH level and LT4 dose
Number of subjects: 33
Study 28911144 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (G1)
Number of subjects: 33
Study 28911144 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (G2)
Number of subjects: 33
Study 26098373 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Coping Power (GCP)
Number of subjects: 360
Study 26098373 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Coping Power (ICP)
Number of subjects: 360
Study 23660727 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion arousal manipulation
Number of subjects: 256
Study 23660727 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician communication behaviors (attending to emotion and framing the decision as the patient's)
Number of subjects: 256
Study 23660727 — intervention group
Group type: COMPARATOR
Intervention: Framing no cardiopulmonary resuscitation as the norm rather than cardiopulmonary resuscitation
Number of subjects: 256
Study 23660727 — intervention group
Group type: COMPARATOR
Intervention: Framing the alternative to cardiopulmonary resuscitation as 'allow natural death' rather than do not resuscitate
Number of subjects: 256
Study 21368651 — intervention group
Group type: EXPERIMENTAL
Intervention: Epi/Epi/Epi
Number of subjects: 65
Study 21368651 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA/Epi/Epi
Number of subjects: 65
Study 21368651 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA/Epi/PCA
Number of subjects: 65
Study 21368651 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA/GA/PCA
Number of subjects: 65
Study 21368651 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 65
Study 19678751 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription dose NAPSO (550 mg twice daily)
Number of subjects: 48
Study 19678751 — intervention group
Group type: EXPERIMENTAL
Intervention: OTC doses of NAPSO (220 mg two or three times daily)
Number of subjects: 48
Study 19678751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 19678751 — intervention group
Group type: EXPERIMENTAL
Intervention: EC‐ASA 81 mg once daily
Number of subjects: 48
Study 17904989 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge group (results of cervical length and fetal fibronectin available)
Number of subjects: 100
Study 17904989 — intervention group
Group type: COMPARATOR
Intervention: Standard group (blinded to cervical length and fetal fibronectin)
Number of subjects: 100
Study 12711264 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal attention (high speech anxious individuals)
Number of subjects: 0
Study 12711264 — intervention group
Group type: COMPARATOR
Intervention: External attention (low speech anxious individuals)
Number of subjects: 0
Study 10919685 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA 134a pMDI
Number of subjects: 119
Study 10919685 — intervention group
Group type: COMPARATOR
Intervention: CFC pMDI
Number of subjects: 119
Study 10919685 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of HFA 134a and CFC pMDI
Number of subjects: 119
Study 10919685 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary efficacy variables
Number of subjects: 119
Study 10919685 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 119
Study 10919685 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning serum cortisol levels
Number of subjects: 119
Study 8873539 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (2 micrograms/kg orally)
Number of subjects: 297
Study 8873539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 1415367 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.6% amino acid solution
Number of subjects: 9
Study 1415367 — intervention group
Group type: COMPARATOR
Intervention: glucose dialysate
Number of subjects: 9
Study 3842628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexabrix 320
Number of subjects: 225
Study 3842628 — intervention group
Group type: EXPERIMENTAL
Intervention: Niopam 300
Number of subjects: 225
Study 3842628 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque 300
Number of subjects: 225
Study 29738746 — intervention group
Group type: EXPERIMENTAL
Intervention: SocketKAP (group B)
Number of subjects: 22
Study 29738746 — intervention group
Group type: EXPERIMENTAL
Intervention: SocketKAP plus anorganic bovine bone minerals (ABBM) (group C)
Number of subjects: 22
Study 29738746 — intervention group
Group type: EXPERIMENTAL
Intervention: SocketKAGE plus ABBM plus SocketKAP (group E)
Number of subjects: 22
Study 29738746 — intervention group
Group type: COMPARATOR
Intervention: Unassisted healing of intact sockets (group A)
Number of subjects: 22
Study 29738746 — intervention group
Group type: EXPERIMENTAL
Intervention: Unassisted healing of sockets with dehiscence (group D)
Number of subjects: 22
Study 26832852 — intervention group
Group type: EXPERIMENTAL
Intervention: AHA peeling combined with pneumatic pressure
Number of subjects: 13
Study 26832852 — intervention group
Group type: COMPARATOR
Intervention: AHA peeling alone
Number of subjects: 13
Study 24411757 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat and sibutramine treatment
Number of subjects: 98
Study 24411757 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat treatment
Number of subjects: 98
Study 22643033 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced walking to music at home for 12 weeks
Number of subjects: 41
Study 22643033 — intervention group
Group type: COMPARATOR
Intervention: Control group (educational information only)
Number of subjects: 41
Study 20164112 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 degrees C saline + magnesium
Number of subjects: 0
Study 20164112 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 degrees C saline
Number of subjects: 0
Study 20164112 — intervention group
Group type: COMPARATOR
Intervention: 37 degrees C saline
Number of subjects: 0
Study 20164112 — intervention group
Group type: COMPARATOR
Intervention: 37 degrees C saline + magnesium
Number of subjects: 0
Study 17510045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 75 microg kg(‐1)
Number of subjects: 100
Study 17510045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 100 microg kg(‐1)
Number of subjects: 100
Study 17510045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 150 microg kg(‐1)
Number of subjects: 100
Study 17510045 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study 16173387 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv treatment
Number of subjects: 46
Study 16173387 — intervention group
Group type: COMPARATOR
Intervention: Drilling
Number of subjects: 46
Study 16173387 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Carisolv and Drilling
Number of subjects: 46
Study 12190173 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (400 microg, two doses)
Number of subjects: 19
Study 12190173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10577696 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy single fraction radiotherapy
Number of subjects: 765
Study 10577696 — intervention group
Group type: COMPARATOR
Intervention: Multifraction radiotherapy (20 Gy/5 fractions or 30 Gy/10 fractions)
Number of subjects: 765
Study 8734698 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antimicrobials (metronidazole or doxycycline) and locally delivered antimicrobials (metronidazole, chlorhexidine)
Number of subjects: 94
Study 1675136 — intervention group
Group type: EXPERIMENTAL
Intervention: Hickman catheters
Number of subjects: 35
Study 1675136 — intervention group
Group type: COMPARATOR
Intervention: Groshong catheters
Number of subjects: 35
Study 1675136 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-lumen catheters
Number of subjects: 35
Study 1675136 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-lumen catheters
Number of subjects: 35
Study 6113351 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective CNS treatment before symptoms arise
Number of subjects: 724
Study 6113351 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic therapy
Number of subjects: 724
Study 6113351 — intervention group
Group type: COMPARATOR
Intervention: Least effective CNS prophylaxis
Number of subjects: 724
Study 6113351 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS prophylaxis
Number of subjects: 724
Study 6113351 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy and better general management
Number of subjects: 724
Study 31765036 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary artery grafting to the left anterior descending artery
Number of subjects: 100
Study 31064336 — intervention group
Group type: EXPERIMENTAL
Intervention: CM education intervention delivered using a website or DVD plus booklet
Number of subjects: 153
Study 31064336 — intervention group
Group type: COMPARATOR
Intervention: Booklet only (Control)
Number of subjects: 153
Study 29203503 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation programme administered by parents between 37 weeks' gestation and 6 months' corrected age
Number of subjects: 0
Study 29203503 — intervention group
Group type: COMPARATOR
Intervention: Nationally recommended follow-up only (control group)
Number of subjects: 0
Study 29203503 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation programme administered by parents
Number of subjects: 0
Study 25727578 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular iPad games
Number of subjects: 50
Study 25727578 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular iPad games (≥8 hours compliance)
Number of subjects: 50
Study 25727578 — intervention group
Group type: COMPARATOR
Intervention: Sham iPad games
Number of subjects: 50
Study 24435893 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial counselling and support lasting 8-12 months after diagnosis
Number of subjects: 330
Study 24435893 — intervention group
Group type: COMPARATOR
Intervention: Follow-up only
Number of subjects: 330
Study 21739119 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin (1.3 mg/m²)
Number of subjects: 75
Study 21739119 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 75
Study 19438584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 683